Atopic dermatitis and psoriasis aﬀect more than 300 million people worldwide. This has a huge impact on patients, their relatives and the health care system.
All patients experience these conditions in a different way as they are highly variable in terms of onset, severity, progression over time and response to treatment.
BIOMAP is analyzing the largest collection of AD and Pso patients data from more than 50,000 Patients using advanced molecular techniques and newly developed tools in bioinformatics to identify biomarkers responsible for variations in disease outcome.
Overall Objectives and Aims
BIOMAP aims at fleshing out the molecular identity and subclasses of the underlying disease subtypes by integrating ‘omics’ data with detailed clinical, environmental and lifestyle information, and to identify candidate biomarkers for patient stratification. To this end, existing data from a wide variety of research studies and trials will be shared, augmented, analysed and followed-up. The specific aims of BIOMAP are:
- To establish a pan-European BioResource for research into inflammatory skin diseases through alignment of clinical data with archived and newly obtained biological specimens.
- To establish a European clinical research network of clinicians, researchers and industry along with patient organisations and other major stakeholders to work in a co-ordinated way to refine clinical definitions and to define relevant and patient-centred outcomes, and to harmonise longitudinal recruitment, deep clinical evaluation and high-quality bio-sampling.
- To build a Data Warehouse assimilating existing and incoming clinical, experimental and omics data from high-quality patient collections, disease registries, epidemiological cohorts and trials with immediate access through a Data Analysis Portal.
- To identify disease subtypes and endotypes and associated signatures.
- To identify key host and environmental factors, and to generate predictive models and biomarkers of relevant disease outcomes.